The information contained within the section of this website is for the purposes of AIM Rule 26:
Please note that hVIVO plc (“hVIVO” or the “Company”, or together with its subsidiaries, the “Group”) changed its name from Retroscreen Virology in April 2015.
Description of the business
hVIVO is an industry leading clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious diseases, specifically leveraging hVIVO’s established human disease challenge models in flu, RSV, HRV and more recently the expansion and development of these models in other respiratory indications for asthma, COPD, cough and related new therapies and in special populations.
Directors and committees
Country of incorporation and main country of operation
hVIVO plc (formerly Retroscreen Virology Group plc) is incorporated in England and Wales (Registration number 08008725). All operations are carried out within the United Kingdom.
Current constitutional documents
Securities in issue
Click here for more information about number of securities in issue and, insofar as the Company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.
UK City Code on Takeovers and Mergers
hVIVO is subject to the provisions of the UK City Code on Takeovers and Mergers.
The Board of hVIVO is responsible for the Group’s corporate governance policies and recognises the importance of this in creating a sustainable, growing and profitable business. The Company has adopted the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”).
Click here for access to the Company’s Corporate Governance Statement – September 2018.
Click here for access to the Company’s Annual and Half-yearly Reports.
Click here to access notifications made by the Company in the last 12 months.
Admission Document and Circulars
Click here to access the Circular, dated 26 November 2015, for Placing of 9,111,111 new Ordinary Shares at 225 pence per share
Click here to access the Circular, dated 14 August 2014, for Placing of 12,923,077 new Ordinary Shares at 260 pence per share
Click here to access the Circular, dated 14 June 2013, for Placing of 12,750,000 new Ordinary Shares at 200 pence per share.
Click here to access the Admission Document in respect of admission to AIM on 3rd May 2012.
Click here for details of the Company’s advisers.